Sonic Healthcare Locks in $445M From Brisbane Lab Sale With $100M Gain
Sonic Healthcare completes $445 million Brisbane laboratory sale
Sonic Healthcare has completed the sale and leaseback of its Brisbane hub laboratory for $445 million, with Charter Hall as the counterparty. The transaction, which was flagged to the market in February 2026, has now settled. The property at 24 Markwell Street, Bowen Hills, Queensland, serves as a national reference centre for highly specialised pathology testing and operates as the main hub laboratory for Sullivan Nicolaides Pathology, the pathology market leader in Queensland and Northern NSW.
The completion provides clarity on balance sheet impact and proceeds timing for this capital release transaction.
When big ASX news breaks, our subscribers know first
What is a sale and leaseback transaction?
A sale and leaseback transaction is a financial arrangement where a company sells a property it owns, then immediately leases it back as a tenant. The business continues operating from the same premises, but converts illiquid real estate into cash whilst maintaining operational use of the asset.
This is a common capital management strategy for asset-heavy businesses seeking to improve return on invested capital. For Sonic, the transaction releases capital tied up in property at a relatively low return, which can then be redeployed into higher-returning opportunities or returned to shareholders.
Lease terms and ongoing costs
Sonic has entered into a triple net lease arrangement with Charter Hall for the Brisbane laboratory. The key terms are:
- Initial annual rent: $25 million per year
- Rent review mechanism: Linked to CPI, capped at 3.5% per annum
- Lease duration: 20-year initial term, with extension options available to Sonic
The CPI-linked rent with a 3.5% cap provides cost certainty for Sonic. Investors can model forward lease expenses with reasonable confidence, as annual increases are limited even if inflation exceeds this threshold.
Financial impact and accounting treatment
Sonic expects to recognise a gain on sale of approximately $100 million before tax under AASB 16 Leases. This gain is excluded from the company’s FY2026 EBITDA guidance.
The tax position is more complex due to Sonic’s accumulated capital losses:
| Financial Item | Amount | Notes |
|---|---|---|
| Gain on sale (before tax, AASB 16) | ~$100m | Excluded from FY26 EBITDA guidance |
| Taxable capital gain | ~$300m | — |
| Accumulated capital losses offset | ~$170m | Previously unrecognised on balance sheet |
| Estimated tax payable | ~$40m | — |
The transaction crystallises value not reflected in Sonic’s financial statements, whilst the capital loss utilisation reduces cash tax leakage. The pre-tax return on the capital released is approximately 5.6%.
Strategic rationale and further transactions
The Brisbane laboratory sale forms part of Sonic’s broader capital management strategy and focus on return on invested capital. By releasing capital invested at approximately 5.6% pre-tax return, management can redeploy proceeds into higher-returning opportunities or return capital to shareholders.
Sonic has advised the market that further property sale and leaseback transactions are under consideration, with potential additional gains on sale. The company also has a conditional heads of agreement in place to sell a surplus Australian property, with settlement expected in the next 12-18 months.
This signals the transaction is part of a broader capital optimisation programme rather than a one-off event. Investors should anticipate further announcements and potential gains as the strategy unfolds.
The Brisbane laboratory’s operational importance
The property at 24 Markwell Street represents critical healthcare infrastructure for Queensland and Australia. It serves as the national reference centre for highly specialised pathology testing, handling complex diagnostic work that requires advanced technical capabilities.
Sullivan Nicolaides Pathology, which operates from this facility, is the pathology market leader in Queensland and Northern NSW. The sale does not affect operations, as Sonic retains full use of the laboratory under the 20-year lease arrangement.
The asset’s strategic importance underpins stable, long-term lease demand. Charter Hall has acquired a high-quality tenant with essential infrastructure, reducing tenancy risk.
The next major ASX story will hit our subscribers first
What this means for investors
The completion of the Brisbane laboratory sale delivers three key outcomes for Sonic shareholders:
-
Immediate capital release: Sonic receives $445 million in proceeds, which can be redeployed into higher-returning opportunities or used for capital management initiatives.
-
Value crystallisation with tax efficiency: The company books approximately $100 million accounting gain (excluded from EBITDA) whilst utilising previously unrecognised capital losses to reduce tax payable to approximately $40 million.
-
Pipeline of further transactions: Management has flagged additional property sale and leaseback opportunities under consideration, plus a surplus property sale expected within 12-18 months.
The transaction demonstrates Sonic’s active approach to balance sheet management and improving return on invested capital. By monetising property assets at relatively low returns, the company creates optionality to pursue higher-value opportunities whilst maintaining operational continuity through long-term lease arrangements.
Don’t Miss the Next Healthcare Market Mover
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment market-moving announcements break across the healthcare sector.